Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical Inc (AMIX) is a pioneer in developing catheter-based neural sensing technologies for neurological disorders. This page provides centralized access to official company announcements, regulatory updates, and breakthrough developments in microchip-enabled medical diagnostics.
Investors and industry professionals will find timely updates on AMIX's R&D milestones, strategic partnerships, and preclinical progress with its proprietary neural signal detection platform. The curated news feed ensures accurate tracking of advancements in minimally invasive neural disorder treatments.
Key updates include regulatory submissions, research collaborations, technology validations, and intellectual property developments. All content is sourced directly from company filings and authorized communications to maintain compliance and reliability.
Bookmark this page for streamlined monitoring of AMIX's progress in redefining neurological diagnostics through its microchip-integrated catheter technology. Check back regularly for verified updates on this development-stage innovator's journey toward clinical impact.
Autonomix (NASDAQ: AMIX) presented post hoc subgroup data from its Proof-of-Concept 1 study at the 2026 ASCO GI symposium showing rapid, durable pain relief for pancreatic cancer patients across Stage 2–4 disease.
Key findings: responding patients showed marked pain reduction within 24 hours; at 7 days, 93.75% (N=16) improved from severe to mild/moderate pain; at 4–6 weeks about two-thirds (N=9) maintained mild/elimination pain; at 3 months no responding patients (N=6) reported severe pain and 50% maintained mild/elimination levels. The analysis included three patients with unknown stage and noted limited longer-term follow-up in some due to disease progression.
Autonomix Medical (NASDAQ: AMIX) announced the European Patent Office granted EP4230133 on Dec 30, 2025 for “Controlled and Precise Treatment of Cardiac Tissues.”
The patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and deliver closed-loop, feedback-driven neuromodulation, denervation, and/or ablation to precisely treat cardiac tissues. The grant complements U.S. Patent No. 12,369,852 and sits alongside the company’s stated IP portfolio of over 80 issued patents and 39 pending applications. The release highlights potential applications across arrhythmias, heart failure, hypertension (including renal–cardiac nerve interplay), ischemia/angina, and plaque/inflammation modulation.
Autonomix Medical (NASDAQ: AMIX) participated in a Virtual Investor CEO Connect segment on Dec 23, 2025. CEO Brad Hauser outlined two strategic priorities:
- Strengthening intellectual property to protect and expand the company’s platform.
- Evaluating multi‑indication opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary, and interventional pain management.
The CEO segment is available online for investors to review.
Autonomix Medical (NASDAQ: AMIX) announced its abstract was accepted for a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA, January 8-10, 2026.
The poster, titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation," is Abstract 693 and will be presented by Robert S. Schwartz, MD, Chief Medical Officer. Session: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract. Presentation times: January 9, 2026, 11:30 AM–1:00 PM and 5:00 PM–6:00 PM PST.
Autonomix Medical (NASDAQ: AMIX) published a new CEO Corner segment on Nov 26, 2025.
In the segment, President and CEO Brad Hauser discussed two priorities: protecting the company’s platform via intellectual property, and exploring expansion beyond its initial pancreatic cancer focus into potential cardiovascular, pulmonary, and chronic pain targets.
The segment is available on the company website for investors and stakeholders seeking management commentary on strategy and pipeline direction.
Autonomix Medical (NASDAQ: AMIX) announced a private placement priced at the market under Nasdaq rules to a single institutional investor expected to close on or about November 19, 2025. The investor will purchase 4,501,666 shares of common stock (or pre-funded warrants) plus unregistered Series C warrants to buy up to 9,003,332 additional shares.
The combined effective offering price per share (with accompanying warrant) is $1.1107. Series C warrants carry an exercise price of $0.8607, are exercisable immediately, and expire 5.5 years after issuance. Gross proceeds are estimated at approximately $5.0 million before placement agent fees and expenses. Maxim Group is sole placement agent. The company will file a resale registration statement for the securities.
Autonomix Medical (NASDAQ: AMIX) announced a post-hoc subgroup analysis of its first-in-human PoC 1 study reporting sustained, clinically meaningful quality-of-life gains after targeted transvascular nerve ablation for severe pancreatic cancer pain.
Key numeric findings: symptom scores improved 14.53 points at 4–6 weeks (n=9) and 26.07 points at 3 months (n=6); functionality rose 8.15 and 25.56 points; global QOL improved 8.33 and 18.06 points. Stage 4/metastatic subgroup exceeded EORTC ≥10-point meaningful-change thresholds at multiple timepoints.
The company said results will inform its multicenter U.S. clinical trial planned to start in 2026.
Autonomix Medical (NASDAQ: AMIX) will be featured in two podium presentations at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Conference in San Francisco on October 25-28, 2025.
The presentations on Monday, October 27, highlight positive initial results from the first-in-human proof-of-concept clinical study evaluating the safety and effectiveness of transvascular energy to ablate targeted nerves to mitigate pain in patients with pancreatic cancer. Presenter: Robert S. Schwartz, MD, FACC. Session times: 7:30 AM PDT at Innovation Theater, Hall E (“Illuminating the Nervous System with Transvascular Precision-Guided Technology”), and 9:00 AM PDT at Station 5, Halls B-C (“Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation”).
Autonomix Medical (NASDAQ: AMIX) will present at the 2025 Maxim Growth Summit in New York on October 22-23, 2025. The company, focused on precision nerve-targeted medical devices, said management will be available for in-person one-on-one meetings with qualified, registered investors during the conference.
The presentation provides an investor-access opportunity to discuss the company’s nerve-sensing and ablation platform and recent developments directly with management. Registration and the full summit agenda are available from the event organizer.
Autonomix (NASDAQ: AMIX) announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,369,852 on October 9, 2025 for "Controlled and Precise Treatment of Cardiac Tissues."
The '852 patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and deliver therapy with closed-loop feedback for precision neuromodulation, denervation, and ablation of cardiac tissues. The filing is described as adding to a global IP portfolio of over 120 issued and pending patent applications and is positioned to address indications including arrhythmias, refractory angina, heart failure, hypertension, and plaque/inflammation modulation.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
